List view / Grid view
Drug Target Review’s Taylor Mixides exclusively interviews Neil Thomas, Partner and Head of Healthcare and Life Sciences for EMEA at Infosys Consulting, on personalised precision medicine, its advances, challenges and the future.
Australian researchers uncover a gene that controls inflammation in kidney disease, which could pave the way for more precise disease diagnostics and personalised treatments.
With advancements in artificial intelligence, precision medicine and gene editing, the field of drug discovery is undergoing a rapid transformation. In this article, Drug Target Review’s Izzy Wood gets the insider knowledge from industry leaders at SLAS 2023, who are experiencing these changes first hand.
Japanese scientists have tested the material used to build models of arteries, revealing their suitability for use in medical education and surgical planning.
The team used these models to show drug responses and established a CRISPR-screening platform to identify potential therapeutic targets for non-alcoholic fatty liver disease.
Explore current insights into the clinical possibilities posed by organoids and delve into short and long-term prospects for therapeutic screening and personalised regenerative medicine in this whitepaper.
What is multiplexed immunofluorescence microscopy imaging?
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
1 November 2022 | By Standard BioTools
Watch our on-demand webinar to hear about advances toward precision medicine through the use of cutting-edge methods and analysing critical patient immune data in response to therapies and disease progression.
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
Compendium of iQue® advanced flow cytometry platform application posters: Antibody discovery and immuno-oncology.
Discover how BioIVT’s portfolio of disease state LEUKOMAX® leukopaks and PBMCs can serve as representative starting materials for autologous cell therapy research.
Learn how R&D Systems™ Avi-tag biotinylated proteins can be used as an alternative to amine biotin coupling in surface plasmon resonance experiments.
Discover how BioIVT’s dissociated tumour cells (DTCs) can be used for tumour-infiltrating lymphocyte (TIL) cell therapy research.
